Medscape22h
FDA OKs Guselkumab for Crohn’s Disease
Guselkumab is the first and only interleukin-23 inhibitor that offers both subcutaneous and intravenous induction options for ...
FDA approves Tremfya for active Crohn's disease in adults
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for adult patients with ...
MPR1d
Tremfya Approved for Moderately to Severely Active Crohn Disease
The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).
The American Journal of Managed Care4d
FDA Approves Guselkumab for Adult Patients With Crohn Disease
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
Healio4d
Tremfya’s FDA win as fully subcutaneous option for Crohn’s may pave way to eclipse Stelara
The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...
WebMD2d
FDA OKs New Crohn’s Treatment You Can Inject at Home
Known as an IL-23 drug, guselkumab reduces inflammation by blocking ... and is a crucial target for therapies managing the disease. Tremfya is the first that also binds to CD64+ cells, providing ...
Fierce Pharma5d
J&J advances Stelara succession scheme with FDA nod for Tremfya in Crohn's disease
With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on ...
Health and Me on MSN1d
FDA Approves Tremfya For Active Crohn's Disease
Crohn's disease is a type of inflammatory bowel disease (IBD) that causes swelling and irritation of the tissues, called ...
Wyoming Tribune Eagle1d
FDA Approves Tremfya for Active Crohn Disease in Adults
The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active ...
U.S. News & World Report1d
FDA Approves Tremfya for Active Crohn Disease in Adults
MONDAY, March 24, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Tremfya (guselkumab) for adult patients with moderately to severely active Crohn disease. This ...